What's in Teva Women's Health's pipeline?

Teva Women's Health has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Teva Women's Health's portfolio?

Top competitors by shared drug class: Astellas Pharma Inc, Organon and Co.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/teva-women-s-health.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Teva Women's Health — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Teva Women's Health pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
DR-103	DR-103	phase 3	Selective estrogen receptor modulator	Estrogen receptor	Women's Health

Therapeutic area mix

Women's Health · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Astellas Pharma Inc · 1 shared drug class
Organon and Co · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Teva Women's Health:

Cite this brief

Drug Landscape (2026). Teva Women's Health — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/teva-women-s-health. Accessed 2026-05-17.